U Hvass1, M F O'Brien. 1. Department of Cardiovascular Surgery, Hôpital Bichat, Paris, France.
Abstract
BACKGROUND: The 5-year follow-up of CryoLife-O'Brien stentless porcine aortic valve xenografts is presented. METHODS: From August 1991 to August 1996, the valve was used in 366 patients. Patients' ages ranged from 18 to 90 years (mean, 73+/-6 years). Survivors were monitored with Doppler echocardiography before discharge, at 6 months, and then annually by the referring cardiologist. Operative and long-term mortality and morbidity were collected using the Edmunds guidelines for reporting morbidity and mortality after cardiac valvular operations. RESULTS: The study was completed during a 6-month period with a 96.5% follow-up, comprising 999 patient-years for a mean follow-up period of 27 months (range, 3 to 64 months). Operative mortality was 6.5%. Linearized rates per patient-year for complications were as follows: structural valve deterioration (0%); thromboembolism (0.5%); prosthetic valve endocarditis (0.2%); valve reoperation (0.8%); and valve-related mortality (0.2%). Sixteen late deaths have occurred. The actuarial survival rate at 5 years was 83%+/-3.5%. CONCLUSIONS: The Cryolife-O'Brien stentless valve has given excellent early hemodynamic and 5-year results.
BACKGROUND: The 5-year follow-up of CryoLife-O'Brien stentless porcine aortic valve xenografts is presented. METHODS: From August 1991 to August 1996, the valve was used in 366 patients. Patients' ages ranged from 18 to 90 years (mean, 73+/-6 years). Survivors were monitored with Doppler echocardiography before discharge, at 6 months, and then annually by the referring cardiologist. Operative and long-term mortality and morbidity were collected using the Edmunds guidelines for reporting morbidity and mortality after cardiac valvular operations. RESULTS: The study was completed during a 6-month period with a 96.5% follow-up, comprising 999 patient-years for a mean follow-up period of 27 months (range, 3 to 64 months). Operative mortality was 6.5%. Linearized rates per patient-year for complications were as follows: structural valve deterioration (0%); thromboembolism (0.5%); prosthetic valve endocarditis (0.2%); valve reoperation (0.8%); and valve-related mortality (0.2%). Sixteen late deaths have occurred. The actuarial survival rate at 5 years was 83%+/-3.5%. CONCLUSIONS: The Cryolife-O'Brien stentless valve has given excellent early hemodynamic and 5-year results.
Authors: Sonya B Seif-Naraghi; Michael A Salvatore; Pam J Schup-Magoffin; Diane P Hu; Karen L Christman Journal: Tissue Eng Part A Date: 2010-06 Impact factor: 3.845